The Thesis
Momentum SMA20 Rider is a trend-following rotation strategy with a clean, testable premise: names trading furthest above their SMA50, while price holds above the SMA20, are in confirmed uptrends worth riding. It ranks a 24-name large-cap universe by distance above SMA50, buys the strongest confirmed uptrends, and cuts positions on one of two triggers — RSI14 above 75 (overbought) or a close below the SMA20 (trend structure broken). When the book is full, capital rotates into higher-ranked names. It is momentum with explicit exit discipline, which is more than many trend systems bother to specify.
Recent Activity
The strategy went live on 2026-08-06, deployed with $10,000. Its initial run executed five buys: JPM (5 sh @ $359.24), ABBV (8 @ $246.20), BAC (31 @ $63.25), V (5 @ $368.54), and MA (3 @ $570.48), leaving $626.50 in cash. The following scheduled run executed zero trades — no new signals cleared the ranking — with total book value at $9,883.70, a slight dip from the starting stake.
One observation worth flagging: those opening five positions lean heavily toward financials (JPM, BAC, V, MA) plus one healthcare name (ABBV). That is what the momentum ranking surfaced on the day, but it means the live book currently carries meaningful sector concentration rather than the diversified spread the 24-name universe might suggest.
A reviewer approved deployment at risk 0.3, calling the momentum-rotation logic safe and correctly sized on cap and cash, while noting minor robustness gaps around missing-budget handling and a null-momentum sentinel.
Backtest and Validation
Over 1,233 days the backtest returned 81% (final equity $18,100.23, 12.89% CAGR) with a Sharpe of 0.98 and a max drawdown of 20.91%. Crucially, the strategy passed 4-fold walk-forward validation — three of four folds positive, with a probabilistic Sharpe ratio of 0.986 and a deflated Sharpe of 0.583 across 24 trials. Out-of-sample results are encouraging: 43.48% return at a 2.18 Sharpe in the most recent fold (2025-05-17 to 2026-08-05), its best stretch by far.
The Risks
The fold breakdown tells the honest story. Performance is uneven: Fold 2 delivered 31.84% at a 1.59 Sharpe, but Fold 3 (2024-02-28 to 2025-05-17) was essentially flat at -0.28% with a 23% drawdown. The strategy shines in trending regimes and stalls in choppy ones — characteristic of momentum.
The 37.13% win rate confirms this is a system that loses often and wins big; it depends on letting winners run, which makes the RSI and SMA20 exits load-bearing. Turnover is extreme at roughly 26,972%, and fees totalled $1,427 across 1,427 trades — friction that compounds. A deflated Sharpe of 0.583, while surviving validation, is a reminder that after accounting for 24 trials the edge is real but not overwhelming.
The verdict: a well-specified, validation-passing momentum strategy with a credible out-of-sample tail — worth watching, provided you accept the drawdown profile and keep an eye on that financials concentration.